To test the hypothesis that the progestogen medrogestone has no effect on changes in lipoprotein metabolism evoked by continuous estrogen replacement therapy, paying special attention to high-density lipoproteins (HDL).
ate the estrogen-induced increase in plasma HDLcholesterol levels (6) . This effect is more marked with nortestosterone-derived progestogens than with those derived from 17-liydroxy-progesterone (5), such as medrogestone (7) (8) (9) .
Previous studies of the effect of medrogestone on lipoprotein levels in postmenopausal women treated with conjugated estrogens had various weaknesses: they either were uncontrolled (8) , included small numbers of patients (7) (8) (9) , or only six cycles were analyzed (7) . We studied hysterectomized postmeno pausal women during 1 year of treatm ent in an open randomized comparative multicenter trial using semiautomated density gradient ultracentrifugation to estimate the changes in lipoprotein subfractions.
MATERIALS AND M ETHODS
Postmenopausal women were recruited by adver tisement and articles in daily newspapers. Women aged 50 to 65 years who had undergone hysterec tomy were eligible for enrollment if they had serum FSH levels >40 mlU/mL (conversion factor to SI unit, 1.00) and serum E2 levels <40 pg/mL (conver sion factor to SI unit, 3.67).
Those who had taken estrogens and/or progesto gens orally <3 months before prestudy screening or had hypersensitivity to estrogens and/or progesto gens were excluded. Smoking >15 cigarettes per day and known alcohol abuse also excluded a subject from participating. In addition, the subjects could not weigh >20% of their ideal weight or have blood pressure (sitting) >160 mm Hg systolic or >90 mm Hg diastolic, serum cholesterol >6.72 mmol/L (con version factor, 38.7), or serum triglycerides >2.84 mmol/L (conversion factor, 88.0). Other exclusion criteria were a Papanicolaou smear of class III or more; thrombophlebitis; thromboembolic disorders related to estrogen therapy; ischemic heart disease; chronic liver, renal, cerebral, or gallbladder disease; malabsorption; evidence of estrogen-dependent neo plasia; and endocrine disease, except for controlled thyroid disease.
Written informed consent was obtained before study entry. The study was approved by the Commit tee of Medical Ethics of all five centers.
Two groups were formed by randomization using a computer program. Fifty-six women used 0.625 mg of conjugated estrogens (CE; Premarin; Wyeth Labo ratories, Hoofddorp, The Netherlands) continuously; 60 women took the same dosage of CE continuously plus 5 mg medrogestone (6,17- an overnight fast (12 to 14 hours). They were centri fuged at 3,000 rpm for 15 minutes at 4°C to obtain serum or plasma. Serum (from Nijmegen only) was ultracentrifuged immediately but the plasma sam ples were snap-frozen in liquid nitrogen and stored at -70°C until ultracentrifugation within 6 months. Spare samples were kept at -20°C for measurement of the apolipoprotein level within 18 months. Two baseline blood samples were taken with >1 week in between. During the study, blood samples were drawn between the 22nd and 28th day of the 3rd, 6th, and 13th cycles. Physical examination, rou tine hematologic and blood chemistry tests, and a urinalysis were performed at baseline and at the end of the study.
Serum FSH and E 2 levels were determined using commercial kits at each site; determinations of lipids for screening and for scientific endpoints were per formed using enzymatic methods (CHOD-PAP cho lesterol reagent and GPO-PAP triglyceride reagent; Boehringer Mannheim, Mannheim, Germany).
The lipoprotein profile was determined in 2 mL serum or plasma, after quick-thawing at 37°C. Den sity gradient ultracentrifugation was performed (10) without previous staining using a 12-mL polypropyl ene tube in a SW40 Ti. rotor for 18 hours at 40,000 rpm at 4°C in a Beckman L7-55 ultracentrifuge (Beckman Instruments, Palo Alto, CA). The top 1.5 mL from the tube was removed by gentle suction with a pipette and stored for further determinations (cholesterol and triglycerides). Further fractionation was performed by using a capillary placed on the bottom of the tube, attached to a micropump and a fraction collector, producing fractions of 250 fiL each. All fractions were weighed (Mettler PM-2000; Mettler-Toledo, Greifensee, Switzerland); the density was determined using a density-measuring cell DMA 602 M (Mettler/Paar, Graz, Austria). Both the scale and the densitometer were linked to a personal computer to calculate the volume of each fraction with three decimal places. A Gilson 222 (Gilson Med ical Electronics S.A., Villiers-le-Bel, France) sample changer and a Dilutor 401 (Gilson Medical Electron ics S.A.) were used for routine purposes. The area under the curve (AUC) comprising the fractions with a density between 1.21 and 1.125 g/mL was used to estimate HDL3-cholesterol; HDL2-cholesterol and LDL-cholesterol were estimated by using the AUC between 1.125 and 1.085 g/mL and the AUC between 1.085 and 1.019 g/mL, respectively. Apolipoproteins (Apo) A-l and B, and lipoprotein (Lp) (a) were deter mined in random fashion by rate immunonephelometry using a Beckman Array Protein system (Beckman Instruments) (11) .
A sample size of 50 women in each treatment group was required to detect a difference in change Values are means ± SD with ranges in parentheses, t Difference between the two groups. $ Quetelet index -(weight in kg)/(height in m)2.
in the key lipid parameters of 0.40 mmol/L in total cholesterol; 0.25 mmol/L in triglyceride; 0.20 mmol/ L in HDL cholesterol and 0.38 mmol/L in LDL cho lesterol with a power of 80% at a level of significance of 0.05 (two-tailed test). The adequacy of the ran domization was assessed by comparing the two treatment groups at baseline using the Student's £-test or Mann-Whitney U-test. The primary efficacy variables were the percentage change from baseline in HDL, total cholesterol, triglycerides, and LDL. An intent-to-treat analysis was performed for all pa tients assigned to treatment who received at least one dose of medication and had at least one efficacy evaluation during therapy.
Analysis of covariance (ANCOVA) was performed on the lipid parameters at each scheduled observa tion with the baseline value as a covariate and treat ment, center, and treatment by center interaction as factors. The assumptions of normality were broken for HDL, triglycerides, and very low-density lipopro tein (VLDL), and these parameters were analyzed with the Mann Whitney [/' -test. Comparisons within treatment groups were made using the paired ¿-test or Wilcoxon matched pairs signed ranks test.
The x 2 test was used for comparisons between groups of the proportion of patients who discon tinued treatment, both overall and for specific rea sons. Vital signs and laboratory data were analyzed by ANCOVA with the baseline value as a covariate and treatment, center, and treatment by center in teractions as factors.
RESULTS
A total of 116 postmenopausal women were en rolled in this trial; none of them took any drugs af fecting lipid metabolism. Fifty-six were assigned randomly to receive CE alone and 60 were assigned to receive CE and medrogestone. Tables 1 and 2 show the clinical characteristics at baseline. Except for VLDL cholesterol, the two groups did not show any statistically significant difference at baseline (Tables 1 and 2 ). Two patients, one from each treat ment group, were excluded because of high 17-/?-E2 at baseline, leaving 55 in the CE group and 59 in the CE and medrogestone group. Thus, 114 patients commenced treatment. Eight women from the CE group and 14 from the CE and medrogestone group withdrew. The primary reasons for withdrawal in the CE group were nausea (n = 1); asthenia, depres sion, and dizziness (n = 1); mastodynia (n = 1); ankle edema (n = 1); and hemangioma in the liver (n = 1). In the CE and medrogestone group the primary rea sons for withdrawal were vertigo (n = 1); exacerba tion of depression (n -1); headache (n = 3); weight gain and dysuria (n = 1); weight gain and itching (n = 1); mastodynia (n = 1); and thrombophlebitis (n = 1). One patient withdrew because of a non-medical event in the CE group. In the CE and medrogestone group three patients withdrew because of medical reasons not attributed to the medication, i.e., hy drops in knee (n = 1); infection in thumb (n = 1); and cholelithiasis (n = 1). Furthermore, in this group one patient failed to return and one patient re quested to withdraw because of nonmedical reasons. Fifty-two patients in the CE group and 51 in the CE and medrogestone group had at least one ontreatm ent lipid assessment. The full 13 cycles of the study were completed by 47 and 41 patients, respec- tively, including four patients of the CE and me drogestone group who had no lipid assessment at cycle 13. Body weight did not change significantly through out the study, and no therapy difference could be discerned. Also, no differences were found in labora tory values such as hematocrit, hemoglobin, platelet count, white cell count, albumin, alkaline phospha tase, calcium, chloride, creatinine, glucose, phospho rus, total bilirubin, potassium, sodium, total protein, and uric acid.
Supine blood pressure at baseline (mean ± SD) in the CE group was 132 ± 17 mm Hg systolic and 81 ± 7.5 mm Hg diastolic and in the CE and medroge stone group was 132 ± 11.5 mm Hg systolic and 82 ± 6.2 mm Hg diastolic. During therapy a slight lowering by 5% at cycle 6 and by 4% at cycle 9 was found in the CE and medrogestone group only (both P < 0.05), but this apparent effect faded thereafter. No difference in change between the two groups was found in this respect. Figure 1 shows a typical ultracentrifugation pat tern before and after three cycles of therapy with CE and medrogestone. Very low-density-lipoprotein cholesterol is omitted in this figure because it had been removed before fractionation. Table 3 shows the percentage changes in the plasma lipid, lipoprotein lipid, and apolipoprotein levels. High-density-lipoprotein cholesterol in creased significantly from baseline at all assess ments in both treatment groups. At cycle 3 and at cycle 13 of therapy, the HDL-cholesterol levels in creased significantly more in the CE group than in the CE and medrogestone group (difference in change P < 0.001 at cycle 3 only), High-density-lipoprotein-2 cholesterol increased significantly from baseline at all assessments in both treatment groups, but between the two groups the difference in the change of HDL2-cholesterol was not signifi cant. The HDL3-cholesterol levels increased signifi cantly from baseline at all assessments in the CE group but not in the CE and medrogestone group. The CE group showed a significantly greater in crease than in the CE and medrogestone group at cycle 3 only (P = 0.011). Similar highly significant increases in the Apo A-l levels were seen in both groups and were not affected by the smaller number of subjects at the end of the study.
The total plasma cholesterol level decreased .sig nificantly more in the CE and medrogestone group than in the CE group at cycles 3 and 6. Plasma tri glyceride levels increased significantly and to a simi lar extent in both treatment groups. Because triglyc eride levels reflect the VLDL concentration, this variable correlated with VLDL cholesterol (not shown). Lipoprotein (a) did not differ from baseline at cycle 13 of therapy in either of the two groups and showed no correlation with any of the other variables.
DISCUSSION
The main purpose of this study was to investigate the effect of medrogestone on the estrogen-induced rise in plasma levels of HDL cholesterol and those of other lipoproteins. Several lines of evidence suggest that HDL inhibits atherogenesis directly or indi rectly or even enhances the regression of plaques: HDL is involved in cholesterol reverse transport (12) ; given IV, HDL inhibits plaque formation in cho lesterol-fed rabbits (12); transgenic mice containing multiple copies of Apo A-l develop less fatty streaks than mice without the extra genes (13); and primary Apo A-l deficiency in human subjects is associated with early ischemic heart disease (14) . The plasma level of HDL cholesterol is the sum of the cholesterol content of two subfractions, the less-dense HDL2 and the denser HDL3. Generally the former is more variable (15) and more sensitive to sex steroids (6) than the latter. This subfractionation does not pro vide more information on cardiovascular risk than the total HDL cholesterol level (15, 16) . However, to gain more insight into the possible mechanisms behind the changes, subfractionation of HDL can be worthwhile. The hepatic triglyceride lipase activity is involved in the conversion of HDL2 into HDL3, and this enzyme is inhibited by estrogens (17) . That would explain the increase in HDL2 but not th at in HDL3. On the other hand, androgenic side effects of a progestogen may enhance hepatic triglyceride lipase activity (6, 17 (7), who performed a randomized, placebo con trolled, double-blind crossover study with 22 partici pants for six cycles. They found no additional effect on HDL subfractions of cyclic 5 mg medrogestone plus 0.625 mg CE when compared with 0.625 mg CE alone, whereas we did. However, this group used a precipitation technique to separate HDL2 from HDL3. Teichmann et al. (8) performed an uncon trolled study of the effect of 5 mg medrogestone plus 1.25 mg CE on lipoprotein lipids and apolipoproteins in 20 oophorectomized patients during 12 cycles. They used a quantitative electrophoretic method to estimate lipoproteins, which did not allow for esti mation of HDL subfractions.
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Plasma total cholesterol level decreased in both groups and significantly more in the CE and me drogestone group than in the CE group in the first three cycles, whereas the decrease in LDL was not significantly different in the two groups. Obviously the explanation for this discrepancy should be that total cholesterol, being the sum of cholesterol all dif ferent classes of lipoproteins, reflects the change in all these classes. Beyond any doubt, changes in LDL cholesterol levels and Apo B levels can be interpreted in terms of cardiovascular risk. The similar decrease in the average LDL cholesterol level and in the Apo B level in both treatm ent groups therefore is reas suring. The clearance of LDL is mainly receptor de pendent, and the LDL receptor activity is enhanced by oral estrogen treatment (20) . Apparently in this
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G evers L euven et al. Medrogestone and lipoproteins study, 5 mg of medrogestone in a cyclic regimen did not attenuate this estrogen effect on the LDL recep tors to an extent sufficient to interfere with the low ering of the plasma LDL levels by estrogens. If me drogestone exerted any androgenic effect in the liver, lower VLDL production (21) and, consequently, de creased LDL synthesis and lower plasma LDL levels would have resulted. However, that has not been found. In fact, fasting plasma triglyceride levels, which reflect the VLDL concentration and VLDL production, were not significantly different between the two groups throughout the treatm ent period. Fi nally, the LDL production rate might have been low ered by an increased clearance of VLDL remnants just before their conversion into LDL. This explana tion is given for the observation in female patients with Familial Dysbetalipoproteinemia, in whom ac cumulated VLDL remnants in plasma can be low ered by oral estrogen therapy (22) . The Lp(a) levels did not differ significantly from baseline at cycle 13. This is in contrast to the obser vational study of Nabulsi et al. (23) who found 13% lower Lp(a) levels among current estrogen users than among nonusers and with a persistent decrease of Lp(a) from baseline during another study of hor mone replacement therapy (24) . It should be remem bered that the effect of sex steroids on Lp(a) may be transient (25) and that we may have missed an eventual decrease in Lp(a). We found no significant correlation between Lp(a) and either LDL choles terol or Apo B.
We conclude that medrogestone given in the dose regimen of this study has little effect on estrogeninduced changes in lipoprotein metabolism and that in these terms no objection can be made against the use of this 17-hydroxyprogesterone-derived proges togen for adjunct treatment in postmenopausal hor mone replacement therapy.
